The mortality of thoracic aortic diseases (mainly aneurysms and dissections) is high, even with surgical treatment. Epidemiology and long-term outcomes are incompletely investigated. Stroke is a major complication contributing to mortality, morbidity, and possibly to reduced quality of life. Study I Increasing incidence of thoracic aortic diseases 1987 – 2002 was demonstrated (n=14229). Annual number of operations increased eight-fold. Overall long-time survival was 92%, 77%, and 57% at 1, 5, and 10 years. Risk of operative and long-term mortality was reduced across time. Study II 2634 patients operated on the proximal thoracic aorta (Swedish Heart Surgery register) were examined. Aortic valve replacement, coronary revascularization, emergency operation, and age were independently associated with surgical death. Long-term mortality was similar for aneurysms and dissections. Operative mortality was reduced (13.7% vs 7.2%) for aneurysms but remained unchanged (22.3% vs 22.4%) for dissections across time. Study III 65 patients underwent selective antegrade cerebral perfusion (SACP) uni- or bilaterally. Stroke was significantly more common after unilateral SACP (29% vs 8%, p=0.045), confirmed by propensity score-matched analysis. Subclavian artery cannulation with Seldinger-technique entailed vascular complication in one case (1.5%). Study IV Near-infrared spectroscopy (NIRS) was used to monitor cerebral tissue saturation (rSO2) during SACP in 46 patients. Lower rSO2 were encountered (1) in patients suffering a stroke (2) with unilateral SACP, and (3) in the affected hemisphere of stroke victims. A decrease of rSO2 by 14 – 21% from baseline increased the risk of stroke significantly. Study V Quality of life (QoL) in 76 survivors of thoracic aortic surgery was examined with the SF-36 health questionnaire. Except for pain, QoL was reduced in all dimensions. QoL was not affected by acuity of operation. Tendencies of lower QoL after descending aortic operations, after major complications, and with persistent dysfunction were non-significant.

Background: Cerebral complications of coronary catheterizations are transient ischemic attack (TIA) and stroke. Silent stroke (SCI) does not cause acute neurological dysfunction. It might cause many disorders including dementia. Sonolysis is therapeutic method. Sonolysis should be the method for reducing the risk of symptomatic and asymptomatic brain ischemic lesions in patients undergoing elective coronary angioplasty or stenting. Aims: To analyse patients with cardiac disease indicated for elective coronary catheterization: 1) Assess the incidence of acute/subacute SCI on brain magnetic resonance (MR) imaging; 2) Investigate factors influencing the frequency and type of microembolic signals (MES) detected using transcranial Doppler (TCD) in patients undergoing elective coronary intervention, and to correlate the frequency and type of MES with detection of new brain ischemic lesions using MR. Examine changes in cognitive function at 30 days post procedure in relation to pretreatment scores; 3) Test the clinical efficacy and safety of perioperative sonolysis in patients undergoing elective coronary catheterization. Methods: 1) 144 patients were enrolled to the study. Brain MR was performed before cardiac intervention. The presence of acute and subacute SCI was evaluated, SCI volume was measured and risk...

INTRODUÇÃO: A análise de eventos clínicos em um ensaio randomizado estabelece a eficácia e segurança de um novo tratamento. Os eventos clínicos são divididos em eventos adversos (EAs) e desfechos clínicos. A literatura é escassa em informações sobre o processo de coleta de eventos clínicos em estudos, bem como sobre a variabilidade entre os centros de pesquisa em reportar eventos clínicos. OBJETIVOS: Descrever todos os eventos clínicos (EAs e desfechos clínicos) reportados pelos centros participantes do estudo APPRAISE-2 (Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome) e caracterizar a sua seriedade. Avaliar a variabilidade entre os centros de pesquisa em reportar eventos clínicos, além de identificar características basais dos participantes associadas ao ato de reportar eventos. MÉTODOS: Os investigadores clínicos foram responsáveis por reportar todos os eventos apresentados pelos participantes em formulários específicos. Formulários para EAs e para cada um dos desfechos clínicos do estudo foram disponibilizados (infarto agudo do miocárdio ou angina instável, acidente vascular encefálico e sangramento). Suspeitas de desfechos clínicos foram enviadas ao comitê de classificação de eventos clínicos (CEC), que as validou de acordo com critérios pré-estabelecidos. Tanto os desfechos clínicos quanto os EAs foram classificados como \"sérios\" ou \"não-sérios\" pelos investigadores clínicos. Para avaliar a variabilidade em reportar eventos clínicos, somente centros com inclusão de >= 10 participantes foram considerados. Modelos estatísticos foram utilizados para avaliar a influência de região geográfica e de características dos participantes na variabilidade entre os centros em reportar eventos. Os dados coletados estão concentrados no Instituto de Pesquisa Clínica da Universidade de Duke, na Carolina do Norte, Estados Unidos. RESULTADOS: Um total de 13.909 eventos clínicos foram reportados por 858 centros de pesquisa em 39 países. A maioria desses eventos foram EAs (91,6%), sendo os demais desfechos clínicos. Dentre os desfechos clínicos reportados, 66,0% foram confirmados pelo CEC. A maior parte dos desfechos confirmados pelo CEC (94,0%) preencheu critérios de seriedade, enquanto que 63,2% dos desfechos negados pelo CEC foram considerados sérios. De todos os EAs, 17,9% foram sérios. O critério de seriedade mais comumente observado foi hospitalização (N=2594), seguido de morte (N=321). Um ajuste para região geográfica explicou 28,7% e 26,4% da variabilidade entre os centros em reportar desfechos clínicos e EA sérios, respectivamente; a adição de características dos participantes ao modelo explicou mais 25,4% da variabilidade entre os centros em reportar desfechos clínicos e 13,4% em reportar EAs sérios. Os ajustes promoveram pouco impacto em explicar a variabilidade em reportar EAs não-sérios. Diversas características clínicas foram associadas ao ato de reportar eventos clínicos. CONCLUSÃO: Em um ensaio clínico multicêntrico de fase III, a maioria dos eventos clínicos reportados foram EAs não-sérios. Região geográfica e características dos pacientes influenciaram a variabilidade entre os centros em reportar desfechos clínicos e EAs sérios, com pouco impacto em EAs não-sérios. Uma coleta integrada de desfechos clínicos e EAs é viável, informativa e ilustra as características que estes eventos compartilham / BACKGROUND: The collection of adverse events (AEs) and clinical endpoints determines the overall efficacy and safety of the study treatment in clinical trials. However, AEs and clinical endpoints are captured and processed separately with limited information on various aspects of this data collection, its integration, and its variation across sites. OBJECTIVES: To describe all site-reported clinical events in the APPRAISE-2 (Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome) trial and report their seriousness. To evaluate the variability in reporting clinical events across sites and identify characteristics associated with clinical event reporting. METHODS: All clinical events were collected in case report forms (CRF) by site-investigators, as AEs or suspected endpoints. Data on suspected endpoints were collected in specific CRFs (myocardial infarction or unstable angina, cerebrovascular event and bleeding) and sent to review by a clinical events committee (CEC) that adjudicated these events according to predefined criteria. Seriousness criteria was collected for all AEs and suspected endpoints. To explore site-level variability i n event reporting, sites with >=10 participants were i ncluded. Statistical models explored the influence of geographic region and patient characteristics in between-site variability in event reporting. All collected data is centered in the Duke Clinical Research Institute, North Carolina, Unites States. RESULTS: A total of 13.909 clinical events were reported by 858 sites in 39 countries. Most clinical events were AEs (91.6%), followed by suspected endpoints. Of suspected endpoints reviewed by CEC, 66.0% were confirmed. Most CEC-confirmed endpoints met serious criteria (94.0%) and, of CEC-negatively adjudicated endpoints, 63.4% were serious. Of all AEs, 17.9% were considered serious events. Hospitalization was the most common criterion for classification as serious event (N=2594), followed by death (N=321). In models accounting for geographic region, site variation in reporting endpoints and serious AEs was explained by 28.7% and 26.4%, respectively; adding patient characteristics further explained site variation by 25.4% for endpoint reporting and 13.4% for serious AE reporting. Non-serious AE reporting variation was not explained by patient characteristics or region. Several clinical characteristics were associated with clinical event reporting. CONCLUSION: In a multicenter phase III clinical trial, the majority of reported events were non-serious AEs. Geographic region and patient characteristics influenced between-site variability in reporting of clinical endpoints and serious AEs, with limited impact in non-serious AEs. An integrated collection of endpoints and AEs is feasible, possible in a multinational trial and illustrates the shared characteristics of events

L'efficacité du rtPA dans le traitement de l’ischémie aigue est bien reconnue avec des effets secondaires graves nécessitant l’évaluation d’autres stratégies. Un modèle d’ischémie cérébrale focale a été décrit, réalisé par injection in situ de thrombine. Dans notre première étude, nous avons utilisé l’imagerie par résonance magnétique multimodale pour documenter les lésions et les zones de pénombre dans ce modèle. Malgré une occlusion de l’artère reproductible et une hypoperfusion marquée chez tous les sujets, une reperfusion spontanée est constatée dans 38% des cas, rendant l’IRM incontournable dans l’évaluation de ce modèle. La deuxième étude a comparé l'efficacité d’un TAFI inhibiteur seul ou en combinaison avec le rtPA à faible dose. Nous avons montré que la combinaison du TAFI inhibiteur avec le rtPA à faible dose n'est pas aussi efficace que la dose standard de rtPA, avec une tendance positive, tandis que le TAFI inhibiteur seul n'est pas efficace du tout. Le modèle thromboembolique présente un intérêt particulier dans l'évaluation des stratégies thérapeutiques associées au rtPA pour améliorer la thrombolyse, surtout lorsqu'il est évalué par un suivi longitudinal en IRM / The benefit of recombinant tissue plasminogen activator (rtPA) treatment in stroke is well known with serious side effects requiring the evaluation of alternative strategies. Injection of thrombin in the middle cerebral artery of mice has been proposed as a new model of thromboembolic stroke. In the first study, we used multiparametric Magnetic Resonance Imaging (MRI), performed immediately after thrombin injection, to document occlusion and area at risk in this model. Despite similar MCA occlusion and marked hypoperfusion, half of animals showed a cortical lesion on DWI, while the other half demonstrated no or very limited lesion. Therefore, MRI measurement of basal lesion size is required to use this animal model in therapeutic studies. The second study compared efficacy between TAFI inhibitor alone and TAFI inhibitor in combination with low-dose rtPA. In conclusion, we showed that the combination of TAFI-I with low-dose rtPA is not as effective as the standard dose of rtPA, with a positive trend, while TAFI inhibition alone is not effective at all. The present thromboembolic model is of particular interest in assessing strategies rtPA association to improve thrombolysis, especially when coupled with longitudinal MRI assessment

INTRODUÇÃO: A análise de eventos clínicos em um ensaio randomizado estabelece a eficácia e segurança de um novo tratamento. Os eventos clínicos são divididos em eventos adversos (EAs) e desfechos clínicos. A literatura é escassa em informações sobre o processo de coleta de eventos clínicos em estudos, bem como sobre a variabilidade entre os centros de pesquisa em reportar eventos clínicos. OBJETIVOS: Descrever todos os eventos clínicos (EAs e desfechos clínicos) reportados pelos centros participantes do estudo APPRAISE-2 (Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome) e caracterizar a sua seriedade. Avaliar a variabilidade entre os centros de pesquisa em reportar eventos clínicos, além de identificar características basais dos participantes associadas ao ato de reportar eventos. MÉTODOS: Os investigadores clínicos foram responsáveis por reportar todos os eventos apresentados pelos participantes em formulários específicos. Formulários para EAs e para cada um dos desfechos clínicos do estudo foram disponibilizados (infarto agudo do miocárdio ou angina instável, acidente vascular encefálico e sangramento). Suspeitas de desfechos clínicos foram enviadas ao comitê de classificação de eventos clínicos (CEC), que as validou de acordo com critérios pré-estabelecidos. Tanto os desfechos clínicos quanto os EAs foram classificados como \"sérios\" ou \"não-sérios\" pelos investigadores clínicos. Para avaliar a variabilidade em reportar eventos clínicos, somente centros com inclusão de >= 10 participantes foram considerados. Modelos estatísticos foram utilizados para avaliar a influência de região geográfica e de características dos participantes na variabilidade entre os centros em reportar eventos. Os dados coletados estão concentrados no Instituto de Pesquisa Clínica da Universidade de Duke, na Carolina do Norte, Estados Unidos. RESULTADOS: Um total de 13.909 eventos clínicos foram reportados por 858 centros de pesquisa em 39 países. A maioria desses eventos foram EAs (91,6%), sendo os demais desfechos clínicos. Dentre os desfechos clínicos reportados, 66,0% foram confirmados pelo CEC. A maior parte dos desfechos confirmados pelo CEC (94,0%) preencheu critérios de seriedade, enquanto que 63,2% dos desfechos negados pelo CEC foram considerados sérios. De todos os EAs, 17,9% foram sérios. O critério de seriedade mais comumente observado foi hospitalização (N=2594), seguido de morte (N=321). Um ajuste para região geográfica explicou 28,7% e 26,4% da variabilidade entre os centros em reportar desfechos clínicos e EA sérios, respectivamente; a adição de características dos participantes ao modelo explicou mais 25,4% da variabilidade entre os centros em reportar desfechos clínicos e 13,4% em reportar EAs sérios. Os ajustes promoveram pouco impacto em explicar a variabilidade em reportar EAs não-sérios. Diversas características clínicas foram associadas ao ato de reportar eventos clínicos. CONCLUSÃO: Em um ensaio clínico multicêntrico de fase III, a maioria dos eventos clínicos reportados foram EAs não-sérios. Região geográfica e características dos pacientes influenciaram a variabilidade entre os centros em reportar desfechos clínicos e EAs sérios, com pouco impacto em EAs não-sérios. Uma coleta integrada de desfechos clínicos e EAs é viável, informativa e ilustra as características que estes eventos compartilham / BACKGROUND: The collection of adverse events (AEs) and clinical endpoints determines the overall efficacy and safety of the study treatment in clinical trials. However, AEs and clinical endpoints are captured and processed separately with limited information on various aspects of this data collection, its integration, and its variation across sites. OBJECTIVES: To describe all site-reported clinical events in the APPRAISE-2 (Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome) trial and report their seriousness. To evaluate the variability in reporting clinical events across sites and identify characteristics associated with clinical event reporting. METHODS: All clinical events were collected in case report forms (CRF) by site-investigators, as AEs or suspected endpoints. Data on suspected endpoints were collected in specific CRFs (myocardial infarction or unstable angina, cerebrovascular event and bleeding) and sent to review by a clinical events committee (CEC) that adjudicated these events according to predefined criteria. Seriousness criteria was collected for all AEs and suspected endpoints. To explore site-level variability i n event reporting, sites with >=10 participants were i ncluded. Statistical models explored the influence of geographic region and patient characteristics in between-site variability in event reporting. All collected data is centered in the Duke Clinical Research Institute, North Carolina, Unites States. RESULTS: A total of 13.909 clinical events were reported by 858 sites in 39 countries. Most clinical events were AEs (91.6%), followed by suspected endpoints. Of suspected endpoints reviewed by CEC, 66.0% were confirmed. Most CEC-confirmed endpoints met serious criteria (94.0%) and, of CEC-negatively adjudicated endpoints, 63.4% were serious. Of all AEs, 17.9% were considered serious events. Hospitalization was the most common criterion for classification as serious event (N=2594), followed by death (N=321). In models accounting for geographic region, site variation in reporting endpoints and serious AEs was explained by 28.7% and 26.4%, respectively; adding patient characteristics further explained site variation by 25.4% for endpoint reporting and 13.4% for serious AE reporting. Non-serious AE reporting variation was not explained by patient characteristics or region. Several clinical characteristics were associated with clinical event reporting. CONCLUSION: In a multicenter phase III clinical trial, the majority of reported events were non-serious AEs. Geographic region and patient characteristics influenced between-site variability in reporting of clinical endpoints and serious AEs, with limited impact in non-serious AEs. An integrated collection of endpoints and AEs is feasible, possible in a multinational trial and illustrates the shared characteristics of events

Zielsetzung In den Industrieländern stellt der Schlaganfall nach kardiovaskulären und Krebs – erkrankungen die dritthäufigste Krankheitsgruppe dar. Im Hinblick auf die Therapie des akuten Schlaganfalls muss die bildgebende Diagnostik schnell und einfach das Ausmaß der zerebralen Ischämie beschreiben können. Ziel dieser Studie war die Einführung und die Validierung eines CT – Protokolls, welches die Diagnostik des akuten Schlaganfalls verbessern soll. Zu diesem CT – Protokoll gehören ein Nativ – CT des Schädels, eine CT – Perfusionsuntersuchung und eine CT – Angiographie. Zusätzlich wollte diese Arbeit herausfinden, ob es physiologische Unterschiede zwischen der grauen Substanz und der weißen Substanz gibt, deren Kenntnis entscheidend für die Auswertung von computertomographischen Perfusionsuntersuchungen sind. Material und Methoden Insgesamt wurden 101 Patienten (Alter von 14 – 94 Jahre, mittleres Alter 69 Jahre) mit einem 8 – bzw. 16 – Zeilen – MSCT (Light Speed Ultra oder Light Speed pro 16, GE Healthcare), die zur Abklärung einer zerebralen Ischämie zum CT vorgestellt wurden, untersucht. Zuerst wurde eine native CT – Serie akquiriert. In der Untersuchung der zerebralen Perfusion wurde eine 2 cm breite Schicht über 60 sec mit 20 intermittierenden Aufnahmen während einer Injektion von 40 ml Kontrastmittel (Iopromid, Jodgehalt von 370 mg) aufgezeichnet. Daran an schloss sich eine CT – Angiographie Untersuchung. Zur Bestimmung des regionalen zerebralen Blutflusses, des regionalen zerebralen Blutvolumens und der mittleren Verweildauer wurden definierte Messfelder (Regions of Interests, ROIs) bestimmt und mit der kontralateralen Hemisphäre verglichen. Ergebnisse Es konnte gezeigt werden, dass der regionale zerebrale Blutfluss und das Blutvolumen im Bereich der Hirnrinde höher sind als im Hirnmark. Insgesamt wurden 66 Patienten mit einer zerebralen Ischämie wurden gefunden. Bei 22 dieser Patienten konnte ein Infarktgeschehen in der Nativ – CT diagnostiziert werden. Diese Ischämien ließen sich auch in der CT – Perfusion mit reduziertem regionalem zerebralem Blutfluss und verlängerter mittlerer Verweildauer nachweisen. Zusätzlich fanden sich 44 Patienten von 101 Untersuchten, die in der CT – Perfusion ein Perfusionsdefizit aufwiesen. Bei diesen Patienten ließ sich kein entsprechendes Korrelat in der Nativ – CT nachweisen. Für 38 dieser 44 Patienten konnte eine CTA durchgeführt werden, wovon für 35 Patienten ein Korrelat zwischen der CT – Perfusion und der CTA gefunden werden konnte. Schlussfolgerung Die Ergebnisse dieser Arbeit zeigen, dass es physiologische Unterschiede zwischen der Hirnrinde und dem Hirnmark gibt, deren Kenntnis für die Bewertung computertomographischer Perfusionsuntersuchungen eine wesentliche Interpretationshilfe darstellt. In Bezug auf die Diagnostik des akuten Schlaganfalls mit der Nativ – CT konnte diese Arbeit zeigen, dass der Nachweis von Infarktfrühzeichen eingeschränkt ist. Mit Hilfe der CT – Perfusion ist es möglich, anhand von zerebralen Perfusionswerten den Schweregrad und die Ausdehnung der zerebralen Ischämie zu bestimmen. Die CT – Angiographie zeigt eine gute Korrelation zur CT – Perfusion, es lassen sich zuverlässig Gefäßverschlüsse darstellen. Im Hinblick auf das weitere Therapievorgehen geben diese Methoden eine wichtige Hilfestellung, etwa zur Überlegung, ob man eine Lysetherapie durchführen sollte oder nicht. / Purpose Stroke is the third – leading cause of death in developed countries, following cardiovascular disease and cancer. There is a need for an easily and rapidly performed technique to detect cerebral ischemia in the first hours after its occurrence. The purpose of this study was the introduction and validation of a Stroke protocol which includes an unenhanced CT scan, a CT Perfusion and a CT Angiography. Furthermore, the purpose of this study was to determine if there is a difference between Perfusion parameters in gray and white matter, which are necessary to know while performing perfusion maps. Data and Methodology A total of 101 patients (age range 14 – 94, average age 69 years) were examined using multiple row CT (8 / 16 row multiple detector, light ultra speed or light speed 16, GE medical systems) for diagnosing cerebral ischemia. First a series of native images was acquired. During the examination of cerebral perfusion a 2 cm wide slab was recorded for 60 sec with 20 intermittent scans following injection of 40 ml of contrast medium with an iodine content of 370 mg / ml. By defining Regions of Interests (ROIs) regional cerebral blood flow (CBF), regional cerebral blood volume (CBV) and mean transit time (MTT) were calculated. Results Physiological regional cerebral blood flow and cerebral blood volume in gray matter were higher than in white matter. In total 66 patients with a cerebral ischemia were found. The unenhanced CT detected 22 patients with cerebral ischemia, which were confirmed by CT Perfusion in all cases. These ischemic areas revealed reduced regional CBF and extended MTT. Furthermore an ischemia correlative was discovered by perfusion analysis for 44 patients (out of 101 investigated) where the extent of the cerebral ischemia had not been visible by unenhanced CT. For 38 out of 44 patients with cerebral ischemia we were able to perform a CTA. For 35 out of these 38 patients, we found a sizable correlation between perfusion maps and CTA. Conclusion There are physiological differences for CT Perfusion parameters between gray and white matter, which are necessary to know for the interpretation of perfusion maps. However, this examination was able to show that unenhanced CT is not always capable of showing early CT signs. With the help of CT perfusion it is possible to detect the extent of acute cerebral ischemia. Furthermore, CT Angiography shows a sizable correlation compared to CT Perfusion. In conjunction, these methods give important Information for the early diagnosis and the therapeutic strategy of ischemic brain injury.

Context. One of the most controversial subjects in anaesthesia today is whether or not neuraxial anaesthesia is more efficient to general anaesthesia in high-risk patients undergoing noncardiac surgery. The cumulative results showed that the incidence of postoperative cardiovascular morbidity and mortality is similar, regardless of type of the anaesthesia. So, is relevant to answer the search question: what is the efficiency of the neuraxial anaesthesia compared with general anaesthesia for lower-limbs revascularization in elderly? Objective. It is to determine the efficiency of the neuraxial anaestheisa versus general anaesthesia for lower-limbs revascularization in elderly. Hypothesis. The hypothesis is that the neuraxial anaestesia is more efficient (OR 0.67) than general anaesthesia for lower-limbs revascularization in elderly. Design. Systematic review with meta-analyse of the original articles of the randomized controlled trials. Setting. Federal University of Alagoas, Maceió, AL. Sample. Original articles of the randomized controlled trials that compared two anaesthetic technique (neuraxial anaesthesia vs. general anaesthesia) in elderly submitted to lower-limbs revascularization surgery. The information was accessed from EMBASE, LILACS, MEDLINE, CINHAL and ISI WEB OF SCIENCE. Main outcomes. Primary outcomes: Mortality, cerebral infarction, myocardial infarction, paralysis and postoperative lower limb amputation rate. Secondary outcomes: Duration of hospital stay, postoperative cognitive dysfunction, postoperative wound infection, other postoperative infections, neuraxial haematoma and complications in the anaesthetic recovery room. Complementary data: internal validity, external validity and statistical analyze. Statistical methods. For data analysis the odds ratio were used in the randon effect model with corresponding 95% confidence interval. / Contexto. A controvérsia atual é saber se a anestesia neuroaxial é mais eficiente do que a anestesia geral em pacientes de alto risco submetidos à cirurgia não cardíaca. Os resultados acumulados mostram que a incidência pós-operatória de mortalidade e morbidade cardiovascular é similar independentemente da técnica anestésica. Assim, é relevante responder a pergunta de pesquisa: qual a eficiência da anestesia neuroaxial comparada à anestesia geral para a revascularização dos membros inferiores em idosos? Objetivo. Determinar a eficiência da anestesia neuroaxial comparada à anestesia geral para a revascularização dos membros inferiores em idosos. Hipótese. A hipótese é que a anestesia neuroaxial é mais eficiente (OR 0,67) quando comparada à anestesia geral para a revascularização de membros inferiores em idosos. Tipo de estudo. Revisão sistemática com metanálise de artigos originais de ensaios clínicos aleatórios. Local. Universidade Federal de Alagoas, Maceió, AL. Amostra. Artigos originais de ensaios clínicos aleatórios que comparam duas técnicas anestésicas (anestesia neuroaxial vs. anestesia geral) em idosos submetidos à cirurgia de revascularização dos membros inferiores. Fontes de informação utilizadas: EMBASE, LILACS, MEDLINE, CINHAL e ISI WEB OF SCIENCE. Variáveis. Variáveis primárias: Mortalidade, infarto cerebral, infarto cardíaco, paralisia muscular e taxa pós-operatória de amputação de membro inferior. Variáveis secundárias: Tempo de duração da internação hospitalar, disfunção cognitiva pós-operatória, infecção pós-operatória, outras infecções pósoperatórias, hematoma neuroaxial e complicações na sala de recuperação pósanestésica. Dados complementares: itens da validade interna, itens da validade externa e análise estatística. Método estatístico. A metanálise foi apresentada com o cálculo das variáveis realizado pela odds ratio no modelo de efeito randômico, com respectivo intervalo de confiança de 95%.

No description available.